Biofrontera AG / Key word(s): Quarter Results/9 Month figures
Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
10-Oct-2019 / 11:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
Leverkusen, Germany, 10.10.2019 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2019.
The Biofrontera-Group generated sales of approximately EUR 18.9 to 19.2 million in the period from January 1st to September 30th, 2019. This corresponds to a sales growth of about 30% compared to the same period last year (EUR 14.6 million).
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
Contact: Biofrontera AG
10-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Hemmelrather Weg 201|
|Phone:||+49 (0)214 87632 0|
|Fax:||+49 (0)214 87632 90|
|ISIN:||DE0006046113, NASDAQ: BFRA|
|Listed:||Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq|
|EQS News ID:||888181|
|End of Announcement||DGAP News Service|